LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    2006: Globally accessible Gene Sequencing Technology

    16/06/2021

    Nominated by: UK BioIndustry Association 

    Organisation in nomination: Solexa: Professor Sir Shankar Balasubramanian and Professor Sir David Klenerman

    Following establishment of UK SME Solexa in 1997, Professor Sir Shankar Balasubramanian and Professor Sir David Klenerman worked to develop their idea to improve the speed and cost of decoding DNA by a factor of 100,000-fold.  In 2004, Solexa acquired Swiss developed molecular clustering technology from Manteia which enabled the amplification of single DNA molecules into clusters, enhancing the fidelity and accuracy of gene sequencing, whilst reducing the cost of the system optics through generation of a stronger signal.

    The first Solexa sequencer, the Genome Analyzer, was launched in 2006 and gave scientists the power to sequence 1 gigabase (Gb) of data in a single run. This 1G sequencer could sequence a personal genome for about $100,000 in three months.

    Solexa became an international public company on NASDAQ,  becoming a $200-million company.  Solexa and its technology were acquired by Illumina in early 2007 for $650 million. In 2015 the technology could sequence a human genome for just $1,000 in about a day – a million-fold improvement on the state-of-the-art at the start of the project in 1997.

    Today the DNA sequencing approach is being used for population scale human genome sequencing as well as large-scale clinical sequencing, such as the NHS 100,000 Genomes Project, and is the global market leader in the field with about 80 percent market share.

    Solexa sequencing has made very large-scale projects possible, and Solexa-Illumina sequencers are the technology that underpins major global projects such as The 100,000 Genomes Project, COVID 19 Variant understanding, the International Cancer Genome Project, and GenomeAsia 100K.

    It is estimated that the Solexa sequencing first envisioned by Klenerman and Balasubramanian is currently used to sequence one million genomes per year.

    References:

    • Solexa: second-gen genetic sequencing, Cambridge Enterprise, Case Study, 13 July 2015
    • Solexa Sequencing, University of Cambridge, Chemistry Success Stories
    • History of sequencing by synthesis – The evolution of the next-generation sequencing technology powering Illumina instruments, Illumina

    Back to the list.

    Share
    Communications Team
    Communications Team
    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.